.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,234,404

« Back to Dashboard

Claims for Patent: 5,234,404

Title: Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
Abstract:Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
Inventor(s): Tuttle; Ronald R. (Escondido, CA), Browne, III; Clinton E. (Oceanside, CA)
Assignee: Gensia Pharmaceuticals, Inc. (San Diego, CA)
Application Number:07/775,735
Patent Claims: 1. A method of eliciting in a mammal immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic activity comprising the administration of an exercise simulating agent with beta adrenergic activity which elicits immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic activity by closed loop drug delivery device.

2. A method of eliciting in a mammal adaptive cardiovascular and metabolic responses similar to the adaptive cardiovascular and metabolic responses elicited by aerobic activity comprising the administration of an exercise simulating agent with beta adrenergic activity which elicits adaptive cardiovascular and metabolic responses similar to the adaptive cardiovascular and metabolic responses elicited by aerobic activity to a mammal by means of closed loop transdermal iontophoretic infusion for 0.5 to 4.0 hours daily, for a period of from 1 to 30 days.

3. The method of claim 2 wherein said exercise simulating agent has the chemical formula: ##STR9## wherein X.sub.1 and X.sub.2 are independently hydrogen, hydroxy, methoxy or carbamoyl, provided that X.sub.1 and X.sub.2 are not both hydrogen or carbamoyl; one of Y.sub.1 and Y.sub.2 is hydrogen and the other is hydrogen or methyl, provided that if Y.sub.1 is methyl, then X.sub.1 is not carbamoyl; Z is hydrogen or hydroxy; and n is 2 or 3; or a pharmaceutically acceptable acid addition salt thereof.

4. The method of claim 3 wherein X.sub.1 is hydrogen, X.sub.2 is hydroxy, Y.sub.1 and Y.sub.2 are hydrogen, Z is hydroxy and n is 3.

5. The method of claim 3 wherein X.sub.1 is hydrogen, X.sub.2 is methoxy, Y.sub.1 and Y.sub.2 are hydrogen, Z is hydroxy and n is 2.

6. A method of eliciting in a mammal immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic exercise which comprises

(a) administering an exercise simulating agent with beta adrenergic activity which elicits immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic exercise to said mammal by a closed loop drug delivery device;

(b) controlling infusion of said exercise simulating agent into the bloodstream of said mammal so that a predetermined range of cardiovascular responses of said mammal is obtained;

(c) monitoring the range of responses of said mammal; and

(d) changing infusion of said exercise simulating agent as required to maintain said range of responses in said mammal.

7. A method of eliciting in a mammal immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic exercise which comprises

(a) administering an exercise simulating agent with beta adrenergic activity which elicits immediate cardiovascular responses similar to those cardiovascular responses elicited by aerobic exercise to said mammal by a closed loop drug delivery device;

(b) controlling infusion of said exercise simulating agent into the bloodstream of said mammal so that a predetermined range of cardiovascular responses of said mammal is obtained;

(c) monitoring the range of responses of said mammal; and

(d) changing infusion of said exercise simulating agent as required to maintain said range of responses in said mammal;

wherein said exercise simulating agent comprises a compound of the formula:

wherein X.sub.1 and X.sub.2 are independently hydrogen, hydroxy, methoxy or carbamoyl, provided that X.sub.1 and X.sub.2 are not both hydrogen or carbamoyl; one of Y.sub.1 and Y.sub.2 is hydrogen and the other is hydrogen or methyl, provided that if Y.sub.1 is methyl, then X.sub.1 is not carbamoyl; Z is hydrogen or hydroxy; and n is 2 or 3; or a pharmaceutically acceptable acid addition salt thereof.

8. The method of claim 7 wherein said predetermined level of response comprises reversible myocardial ischemia when coronary artery disease is present.

9. The method of claim 8 wherein said closed loop drug delivery device comprises an intravenous drug delivery device.

10. The method of claim 8 wherein said closed loop drug delivery device comprises a transdermal iontophoretic device.

11. The method of claim 8 wherein said exercise simulating agent is a compound wherein Z is hydroxy.

12. The method of claim 11 wherein said exercise simulating agent is a compound wherein X.sub.1 is hydrogen, X.sub.2 is hydroxy, Y.sub.1 and Y.sub.2 are both hydrogen and n is 3.

13. The method of claim 11 wherein said exercise simulating agent is a compound wherein X.sub.1 is hydrogen, X.sub.2 is methoxy, Y.sub.1 and Y.sub.2 are hydrogen and n is 2.

14. A method for increasing cardiac contractility in a mammal having depressed cardiac contractility which comprises administering to said mammal an effective amount of a compound of the formula: ##STR10## wherein X.sub.1 and X.sub.2 are independently hydrogen, hydroxy, methoxy or carbamoyl, provided that X.sub.1 and X.sub.2 are not both hydrogen or carbamoyl; one of Y.sub.1 and Y.sub.2 is hydrogen and the other is hydrogen or methyl, provided that if Y.sub.1 is methyl, then X.sub.1 is not carbamoyl; and n is 2 or 3; or a pharmaceutically acceptable addition salt thereof.

15. The method according to claim 14 wherein X.sub.1 is hydrogen, X.sub.2 is carbamoyl, Y.sub.1 is methyl, Y.sub.2 is hydrogen and n is 2.

16. A method for causing adaptive effects in a mammal which are similar to adaptive responses of said mammal (caused by aerobic exercise over a period of time which comprises administering to said mammal an effective amount of a compound of the formula: ##STR11## wherein X.sub.1 and Y.sub.2 are independently hydrogen, hydroxy, methoxy or carbamoyl, provided that X.sub.1 and X.sub.2 are not both hydrogen or carbamoyl; one of Y.sub.1 and Y.sub.2 is hydrogen and the other is hydrogen or methyl, provided that if Y.sub.1 is methyl, then X.sub.1 is not carbamoyl; and n is 2 or 3; or a pharmaceutically acceptable acid addition salt thereof.

17. The method of claim 16 wherein X.sub.1 is hydrogen, X.sub.2 is hydroxy, Y.sub.1 and Y.sub.2 are hydrogen and n is 3.

18. The method of claim 16 wherein X.sub.1 is hydrogen, X.sub.2 is methoxy, Y.sub.1 and Y.sub.2 are hydrogen and n is 2.

19. The method of claim 16 wherein X.sub.1 is hydrogen, X.sub.2 is carbamoyl, Y.sub.1 is methyl, Y.sub.2 is hydrogen and n is 2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc